It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JCRRF’s FA Score shows that 1 FA rating(s) are green whileMIRA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MIRA’s TA Score shows that 4 TA indicator(s) are bullish.
JCRRF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while MIRA (@Pharmaceuticals: Major) price change was -1.91% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -4.55%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was +2.00%.
MIRA is expected to report earnings on Nov 27, 2024.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
JCRRF | MIRA | JCRRF / MIRA | |
Capitalization | 1.2B | 16.3M | 7,344% |
EBITDA | 7.45B | -6.82M | -109,323% |
Gain YTD | -49.447 | 46.667 | -106% |
P/E Ratio | 44.05 | N/A | - |
Revenue | 34.3B | 0 | - |
Total Cash | 13.3B | 5.87M | 226,653% |
Total Debt | 22.8B | 109K | 20,917,431% |
MIRA | |
---|---|
RSI ODDS (%) | 4 days ago90% |
Stochastic ODDS (%) | 4 days ago67% |
Momentum ODDS (%) | 4 days ago90% |
MACD ODDS (%) | 4 days ago90% |
TrendWeek ODDS (%) | 4 days ago90% |
TrendMonth ODDS (%) | 4 days ago76% |
Advances ODDS (%) | 20 days ago86% |
Declines ODDS (%) | 5 days ago90% |
BollingerBands ODDS (%) | 4 days ago90% |
Aroon ODDS (%) | 4 days ago90% |
A.I.dvisor tells us that JCRRF and SNYNF have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JCRRF and SNYNF's prices will move in lockstep.
Ticker / NAME | Correlation To JCRRF | 1D Price Change % | ||
---|---|---|---|---|
JCRRF | 100% | N/A | ||
SNYNF - JCRRF | 8% Poorly correlated | N/A | ||
SCLX - JCRRF | 4% Poorly correlated | -10.31% | ||
MIRA - JCRRF | 2% Poorly correlated | +2.67% | ||
CSWYF - JCRRF | 0% Poorly correlated | N/A | ||
VRBCF - JCRRF | -0% Poorly correlated | N/A | ||
More |
A.I.dvisor tells us that MIRA and RHHBF have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MIRA and RHHBF's prices will move in lockstep.
Ticker / NAME | Correlation To MIRA | 1D Price Change % | ||
---|---|---|---|---|
MIRA | 100% | +2.67% | ||
RHHBF - MIRA | 8% Poorly correlated | -1.66% | ||
OGN - MIRA | 8% Poorly correlated | -1.83% | ||
RHHVF - MIRA | 8% Poorly correlated | -3.12% | ||
JNJ - MIRA | 8% Poorly correlated | +1.40% | ||
SNYNF - MIRA | 7% Poorly correlated | N/A | ||
More |